144 related articles for article (PubMed ID: 27237331)
1. Noscapine and its Analogs as Chemotherapeutic Agent: Current updates.
Tomar V; Kukreti S; Prakash S; Madan J; Chandra R
Curr Top Med Chem; 2017; 17(2):174-188. PubMed ID: 27237331
[TBL] [Abstract][Full Text] [Related]
2. Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms.
Nourbakhsh F; Askari VR
Biofactors; 2021 Nov; 47(6):975-991. PubMed ID: 34534373
[TBL] [Abstract][Full Text] [Related]
3. A review on noscapine, and its impact on heme metabolism.
Singh H; Singh P; Kumari K; Chandra A; Dass SK; Chandra R
Curr Drug Metab; 2013 Mar; 14(3):351-60. PubMed ID: 22935070
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
5. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.
Ke Y; Ye K; Grossniklaus HE; Archer DR; Joshi HC; Kapp JA
Cancer Immunol Immunother; 2000 Jul; 49(4-5):217-25. PubMed ID: 10941904
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Mishra RC; Gundala SR; Karna P; Lopus M; Gupta KK; Nagaraju M; Hamelberg D; Tandon V; Panda D; Reid MD; Aneja R
Bioorg Med Chem Lett; 2015; 25(10):2133-40. PubMed ID: 25891106
[TBL] [Abstract][Full Text] [Related]
7. The anti-cancer activity of noscapine: a review.
Mahmoudian M; Rahimi-Moghaddam P
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):92-7. PubMed ID: 19149691
[TBL] [Abstract][Full Text] [Related]
8. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer.
Alisaraie L; Tuszynski JA
Chem Biol Drug Des; 2011 Oct; 78(4):535-46. PubMed ID: 21781284
[TBL] [Abstract][Full Text] [Related]
9. Noscapinoids bearing silver nanocrystals augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in B16F1, mouse melanoma skin cancer cells.
Soni N; Jyoti K; Jain UK; Katyal A; Chandra R; Madan J
Biomed Pharmacother; 2017 Jun; 90():906-913. PubMed ID: 28441716
[TBL] [Abstract][Full Text] [Related]
10. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation.
Zhou J; Gupta K; Aggarwal S; Aneja R; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2003 Apr; 63(4):799-807. PubMed ID: 12644580
[TBL] [Abstract][Full Text] [Related]
11. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site.
Naik PK; Santoshi S; Rai A; Joshi HC
J Mol Graph Model; 2011 Jun; 29(7):947-55. PubMed ID: 21530342
[TBL] [Abstract][Full Text] [Related]
12. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs.
Zughaier S; Karna P; Stephens D; Aneja R
PLoS One; 2010 Feb; 5(2):e9165. PubMed ID: 20161797
[TBL] [Abstract][Full Text] [Related]
13. Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs.
Kumar S; Sagar B; Gaur A; Shukla S; Pandey E; Gulati S
Anticancer Agents Med Chem; 2023; 23(6):624-641. PubMed ID: 35927808
[TBL] [Abstract][Full Text] [Related]
14. Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents.
Manchukonda NK; Naik PK; Santoshi S; Lopus M; Joseph S; Sridhar B; Kantevari S
PLoS One; 2013; 8(10):e77970. PubMed ID: 24205049
[TBL] [Abstract][Full Text] [Related]
15. Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model.
Pragyandipta P; Pedapati RK; Reddy PK; Nayek A; Meher RK; Guru SK; Kantevari S; Naik PK
Chem Biol Interact; 2023 Sep; 382():110606. PubMed ID: 37330181
[TBL] [Abstract][Full Text] [Related]
16. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
17. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog.
Aneja R; Vangapandu SN; Joshi HC
Bioorg Med Chem; 2006 Dec; 14(24):8352-8. PubMed ID: 17008104
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.
Aneja R; Vangapandu SN; Lopus M; Viswesarappa VG; Dhiman N; Verma A; Chandra R; Panda D; Joshi HC
Biochem Pharmacol; 2006 Aug; 72(4):415-26. PubMed ID: 16780803
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of N-3-Br-benzyl-noscapine and docetaxel abrogates oncogenic potential of breast cancer cells.
Dash SG; Kantevari S; Pandey SK; Naik PK
Chem Biol Drug Des; 2021 Sep; 98(3):466-479. PubMed ID: 34107169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
